Compare Eli Lilly And Co (LLY) vs Williams-Sonoma, Inc. (WSM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eli Lilly And Co vs Williams-Sonoma, Inc. — how do they compare? Eli Lilly And Co trades at $1,163 (market cap $1.02T), while Williams-Sonoma, Inc. trades at $221.37 (market cap $26.30B). The key difference: Eli Lilly And Co is far larger — about 38.8× Williams-Sonoma, Inc.'s market cap, and Williams-Sonoma, Inc. pays the higher dividend (1.36%). Which is the better fit depends on your goals.
| LLY | WSM | |
|---|---|---|
Market Cap | $1.02T | $26.30B |
Sector | Health | Consumer Cyclical |
52-Week High | $1.24K | $240.06 |
52-Week Low | $625.65 | $168.64 |
Enterprise Value | $1.06T | $27.14B |
Dividend Yield | 0.6% | 1.36% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,150.86, down 2.39% on the day, with a bullish technical signal from moving averages and strong fundamental performance. The company reported robust earnings beats in recent quarters, with Q1 2026 EPS of $8.55 exceeding expectations by 23%. Revenue surged to $65.18 billion in 2025, driving a net income margin of 34.99%. Recent news highlights LLY's $2.8 billion acquisition of AtaiBeckley to expand its neuroscience pipeline, signaling strategic growth in mental health treatments.
Outlook remains positive with analyst consensus price target of $1,380 implying 20% upside, supported by 73% buy ratings. Key risks include high valuation multiples (P/E 41.89) and rising debt levels, though operating cash flow growth to $16.81 billion in 2025 provides financial flexibility. Investors should monitor Q2 2026 earnings on August 5 for continued execution on weight-loss drug demand and integration of recent acquisitions.
Williams-Sonoma (WSM) trades at $223.34, down 2.22% today, with a bullish technical signal from moving averages but neutral oscillators. The company maintains strong profitability with 13.81% net margins and 54.01% ROE, though revenue has declined from $8.7B in 2023 to $7.7B in 2025. Recent earnings beats and consistent dividend payments highlight operational strength amid competitive retail pressures.
WSM presents a mixed outlook with solid fundamentals but faces revenue headwinds and high valuation multiples. Analyst consensus is cautious with 60.72% hold ratings and a $215.22 price target below current levels. Key risks include consumer discretionary spending volatility and execution challenges in maintaining premium positioning against competitors like RH.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →About Williams-Sonoma, Inc.
With a wide retail and direct-to-consumer presence, Williams-Sonoma is a leader in the $300 billion domestic home category, focused on expanding its exposure in the B2B, marketplace, and franchise areas. Namesake Williams-Sonoma (175 stores) offers high-end cooking essentials, while Pottery Barn (189) provides casual home accessories. Brand extensions include Pottery Barn Kids (52) and PBteen. West Elm (121) is an emerging concept for young professionals, and Rejuvenation (9) offers lighting and house parts. Williams-Sonoma also has a business-to-business team that supports projects that range from residential to large-scale commercial.
Read more on WSM →
